Baylor College of Medicine: PKMYT1, a Potential 'Achilles Heel' of Treatment Resistant ER+ Breast Cancers With the Poorest Prognosis
May 25, 2024
May 25, 2024
HOUSTON, Texas, May 25 (TNSres) -- The Baylor College of Medicine issued the following news:
Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha. Although these estrogen receptor-positive (ER+) breast cancers often initially respond to standard treatment that combines endocrine therapies with CDK4/6 inhibitors, drug resistance often develops leading to lethal metastatic disease that spreads from the breast and does not respond to avai . . .
Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha. Although these estrogen receptor-positive (ER+) breast cancers often initially respond to standard treatment that combines endocrine therapies with CDK4/6 inhibitors, drug resistance often develops leading to lethal metastatic disease that spreads from the breast and does not respond to avai . . .